168. Neuroadaptations to Antipsychotic Drugs: Optimizing use of Current Medication Through a Deeper Understanding of Antipsychotic Drug Action in the Brain and Body

摘要

>Overall Abstract: Antipsychotic drugs, all of which block the dopamine D2 receptor to a greater or lesser extent, are the mainstay for the pharmacological treatment of schizophrenia. Engaging in a deeper understanding of how antipsychotics act on the brain and body, at the cellular, molecular and physiological level is vital to comprehend both the beneficial and the potentially harmful actions of these medications and importantly stimulate development of novel therapeutics. To address this timely and clinically relevant issue, we propose 4 talks covering the most up-to-date clinical and preclinical data focusing on (1) antipsychotic treatment efficacy and failure, (2) brain-mediated cardiometabolic side effects, (3) evidence from human postmortem studies that attempt to dissect neuropathological effects of antipsychotic drugs from organic schizophrenia neurobiology, and (4) the emerging interactions of antipsychotic drugs with the immune system. The 4 proposed speakers are:(1) Dr Davide Amato: “Effects of antipsychotic treatment on synaptic dopamine levels and its relevance for antispychotic treatment efficacy and failure: preliminary results from a meta-analysis of microdialysis studies”(2) Dr Margaret Hahn: “Olanzapine impairs central insulin action leading to dysregulation of hepatic glucose production”(3) Dr Clare Beasley: “Post-mortem studies of glial pathology: dissecting drug from disease effects”(4) Dr Anthony Vernon “Do antipsychotics inflame the brain?”The final part of the workshop will then be given over to an open discussion led by the chair, cochair, and moderator with the workshop audience.Professor Gary Remington will chair the session and Professor Lars Jarkog has agreed to act as moderator / discussant.Our aim is to stimulate discussion on these highly clinically relevant topics and consider how we might use current and evolving knowledge and new methodologies in the fields of neuropharmacology and neuroscience, to advance our understanding of the long-term impact of antipsychotic treatment. Ultimately, this may inform the clinical use of these drugs and pave the way for development of novel treatment strategies or optimized antipsychotic drugs.